Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pul-Sar is a Russian medical device and biotechnology company specializing in the development and manufacture of innovative surgical products for hemostasis and lymphostasis. Operating as the production division of the Institute for Applied Medical Research (IAMR) in the Dubna Special Economic Zone, the company produces unique, clinically-proven solutions such as Haemoblock® and Lymphoblock®. Haemoblock® is a versatile local hemostatic agent containing a partial silver salt of polyacrylic acid that stops capillary and parenchymal bleeding, while Lymphoblock® is designed to prevent and manage lymphorrhea and seromas during major surgeries. These products are non-toxic, biocompatible, and widely utilized across hundreds of medical institutions globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pul-Sar.